Richard Perlman
Cardiovascular Disease · Voorhees, NJNPI 1568433084
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $547 and has fallen 62.5% since, to $205 in 2023. That places this record below the midpoint for cardiovascular disease clinicians in NJ, where the typical reported total is $2,633.
Across 74 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$268
- Johnson & Johnson$196
- Novartis$154
- Pfizer$114
- Abbott$76
- Boston Scientific$74
- plus $293 from 10 others
Across 41 payments — averaging $4438.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$79K
- Pfizer$43K
- Novartis$31K
- Merck$19K
- AstraZeneca$6K
- Boehringer Ingelheim$5K
What the payments were for
- Food & beverage$1,174100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 18 | $268 |
| Johnson & Johnson | 7 | $196 |
| Novartis | 11 | $154 |
| Pfizer | 17 | $114 |
| Abbott | 1 | $76 |
| Boston Scientific | 3 | $74 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $73 |
| Edwards Lifesciences | 1 | $49 |
| Merck | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$113
How this compares
$1,174 in reported general payments places this provider in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $31,424 |
| Metoprolol Succinate | 17 | $290 |
| Rosuvastatin Calcium | 13 | $221 |
| Atorvastatin Calcium | 15 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $114 | $31,42423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Voorhees
- Elias IliadisVoorhees$158K
- Joseph ParrilloVoorhees$58K
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.